Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CMS Opens National Coverage Analysis For Percutaneous Image-Guided Lumbar Decompression

This article was originally published in The Gray Sheet

Executive Summary

The Medicare agency is requesting public comment on the clinical evidence of short-term and long-term health benefit outcomes of this procedure to diagnose and treat lumbar spinal stenosis.

You may also be interested in...

Reimbursement Briefs: CMS Restricts Coverage For PILD Spine Surgery; OIG News

Medicare will only cover percutaneous image-guided lumbar decompression as part of qualifying clinical trials under a final national coverage determination. OIG scrutinizes Medicare Administrative Contractor performance and local coverage determination inconsistencies. More reimbursement briefs.

Spine Firms Make Last-Ditch Appeals For CMS Support Of Percutaneous Lumbar Decompression

Two medical device makers that stand to lose under CMS’ proposed noncoverage of percutaneous image-guided lumbar decompression say the agency’s proposal would unwisely eliminate a promising alternative to invasive surgery for the treatment of lumbar spinal stenosis. One suggests coverage with evidence development to allow more data collection, an approach also advocated by the North American Spine Society.

CMS Proposes Noncoverage For Percutaneous Image-guided Lumbar Decompression

The procedure, aimed at treating lumbar spinal stenosis, is not reasonable and necessary, the Medicare agency says. A final decision is due Jan. 15.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts